2024-07-12 16:59:26 ET
Summary
- Abeona Therapeutics Inc.'s BLA resubmission of Pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa is expected 2nd half of 2024.
- If Pz-cel is approved by the FDA, the company believes that it could reach peak U.S. sales of >$500 million by year 5 of the gene therapy being sold.
- FDA approval of Pz-cel for RDEB would allow Abeona to obtain a Priority Review Voucher, which it could keep or sell to another company for a considerable amount of cash.
- Deal made with Beacon to advance AAV204 Capsid for use against select ophthalmology targets.
Abeona Therapeutics Inc. ( ABEO ) is gearing up for a Biologics License Application [BLA] resubmission in the 2nd half of 2024. This would be regarding a resubmission of the BLA filing of Pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa [RDEB]....
Read the full article on Seeking Alpha
For further details see:
Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones